Can you provide an example of how the BioFire RP2 Panel can influence therapy decisions?
Not long after instituting the BioFire RP2 Panel, we had a patient who presented acutely ill to our emergency department with fever and significant respiratory distress, requiring intubation and immediate transfer to the intensive care unit.
The patient was immediately and appropriately started on broad-spectrum antibiotics consisting of linezolid and cefepime. Within two hours of hospitalization, the RP2 indicated the presence of human metapneumovirus from the patient’s nasopharyngeal swab.
It was the clinical presentation coupled with understanding the pathogen and confidence in the pathogen-identification system that led us to conclude that this patient’s illness was due to human metapneumovirus, and also to discontinue the broad-spectrum antibacterial therapy. Within two hours of being at our hospital, we were able to tell the family that we had identified the causative pathogen and were doing everything possible for the patient.
Over the next two weeks, the patient recovered and was discharged without exposure to a prolonged course of broad-spectrum antibiotics that he did not need, and without having to endure toxicities such as Clostridium difficile-associated diarrhea. The BioFire technology enabled us to provide the best care for this patient.